Laboratory assessments — from preclinical research through post-marketing surveillance — determine whether a cell-based therapy for cancer succeeds or fails.
Showcasing our IQVIA Connected Intelligence and joint expertise and capabilities, Q2 Solutions' Alan Wookey and IQVIA's Diego Correa were recently featured in the peer-reviewed scientific journal Nature to share their thoughts on key components of a comprehensive clinical development plan for cell therapy clinical trials.
In this paper, Alan and Diego discuss the important role complex laboratory assessments play, from preclinical research through post-market surveillance, in determining the likelihood of success for cell-based therapies for the treatment of cancer. Given the complexities of cell therapy development, Alan and Diego highlight how a thorough plan with collaboration among key expertise from IQVIA and Q2 Solutions, customized therapy-specific assays, harmonized oversight of intricate lab assessment timetables throughout the full trial lifecycle and more are keys to success.
We encourage you to read the full paper here.
In this episode Dr. Monika Lamba Saini and Bruno Larvol of “LARVOL & Friends” discuss the role of artificial intelligence (AI) in pathology and its potential impact on healthcare. They delve into...
Subject samples are the lifeblood of your clinical trials. To be successful, you need a unique solution that can track samples through their full lifecycles — across the ecosystem of sites, labs,...
Recently expanded to nearly 165,000-square-feet, our state-of-the-art laboratory is equipped with a broad spectrum of enhanced scientific solutions for genomics, flow cytometry, translational science...